PB2101 Indirect treatment comparison of emicizumab versus efanesoctocog alfa prophylaxis in pediatric people with severe hemophilia A

Emicizumab and efanesoctocog alfa are approved for the treatment of adults and pediatric people with hemophilia A (PwHA). Head-to-head trials have not been conducted; indirect treatment comparisons (ITCs) can, in part, account for a lack of head-to-head trials. No published ITCs have focused on these two treatments in pediatric PwHA.